Search
Dasiprotimut-T
go.drugbank.com/drugs/DB17287ExperimentalDasiprotimut-T is a personalized therapeutic vaccine against B-cell lymphomas.[A254701] It has been investigated in clinical trials.
Synonyms: Dasiprotimut-TCategories: dasiprotimut-Tα-Methylacetylfentanyl
go.drugbank.com/drugs/DB01532ExperimentalIllicitIt was categorized under the Schedule I in the US and it was illegally sold in early 1980. α-Methylacetylfentanyl synthesis process is very similar to α-methylfentanyl with the substitution of the acetic
R411
go.drugbank.com/drugs/DB05468ExperimentalIt is not immunosuppressive, but blocks the activation and recruitment of cells involved in respiratory inflammation. … It is a dual-acting competitive integrin antagonist (as compared to previously developed single integrin antagonists or SIAs) that prevents binding of V-CAM1 to either a4b1 or a4b7.
Tetrafluoroborate
go.drugbank.com/drugs/DB16340InvestigationalTetrafluoroborate is under investigation in clinical trial NCT02907073 (Positron Emission Tomography (PET) Imaging Studies With NIS Reporter).
Detomidine
go.drugbank.com/drugs/DB11556InvestigationalVet approvedCurrently, it is only approved by the FDA for use in horses but has been studied for use in other large animals. … Normally, it is administered in the salt form, detomidine hydrochloride. This drug is prescribed by veterinarians and is marketed as _Dormosedan_.
Adlinacogene civaparvovec
go.drugbank.com/drugs/DB16788Investigational[L46711] Developed by Sangamo Therapeutics Inc., it is being investigated for the treatment of hemophilia B.[L46706] … It uses proprietary zinc finger nuclease (ZFN) genome editing to insert into the DNA of liver cells a copy of the F9 gene, which controls the production of Factor IX.
OPC-14523
go.drugbank.com/drugs/DB05422ExperimentalOPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.
Laquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally. … It is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.